Skip to main content

Table 1 Distribution of 4483 study participants according to selected variables and markers of HCV

From: Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy

Characteristics Overall Anti-HCV Anti-HCV+ Anti-HCV+ and HCV RNA+
(n = 4483) (n = 4147) (n = 336) (n = 246)
N (%) N (%) N (%) p-value vs Anti-HCV N (%) p-value vs Anti-HCV
Sex
 Female 2478 (55.3) 2304 (55.6) 174 (51.8)   128 (52.0)  
 Male 2005 (44.7) 1843 (44.4) 162 (48.2) 0.18 118 (48.0) 0.28
Age at enrollment (years)
  < 50 2604 (58.1) 2565 (61.9) 39 (11.6)   26 (10.6)  
 50–59 736 (16.4) 680 (16.4) 56 (16.7)   43 (17.5)  
 60–69 552 (12.3) 455 (11.0) 97 (28.9)   73 (29.7)  
  ≥ 70 591 (13.2) 447 (10.8) 144 (42.9) < 0.01 104 (42.3) < 0.01
Education (years)a
  < 9 2693 (62.0) 2425 (60.2) 268 (84.8)   198 (86.1)  
  ≥ 9 1654 (38.0) 1606 (39.8) 48 (15.2) < 0.01 32 (13.9) < 0.01
HBV
 HBsAg 4383 (97.8) 4052 (97.7) 331 (98.5)   241 (98.0)  
 HBsAg+ 100 (2.2) 95 (2.3) 5 (1.5) 0.34 5 (2.0) 0.79
Fasting plasma glucose (mg/dl)a
  < 126 4148 (93.1) 3857 (93.6) 291 (86.9)   207 (84.5)  
  ≥ 126 309 (6.9) 265 (6.4) 44 (13.1) < 0.01 38 (15.5) < 0.01
eGFR (ml/min/1.73m2)a
  < 60 203 (4.6) 165 (4.0) 38 (11.3)   26 (10.6)  
  ≥ 60 4254 (95.4) 3957 (96.0) 297 (88.7) < 0.01 219 (89.4) < 0.01
FIB-4 index scorea
  < 1.45 3540 (79.6) 3437 (83.6) 103 (30.7)   62 (25.2)  
 1.45–3.25 777 (17.5) 622 (15.1) 155 (46.3)   113 (45.9)  
  > 3.25 131 (2.9) 54 (1.3) 77 (23.0) < 0.01 71 (29.9) < 0.01
Follow-up (years)
 Median (IQR) 12.7 (11.9–13.6) 12.7 (11.9–13.6) 12.1 (7.0–13.2)   11.7 (6.2–13.2)  
 Total person-years 52,176.6 48,786.8 3389.8   2375.2  
  1. Abbreviations: eGFR Estimated Glomerular Filtration Rate, HCV hepatitis C virus, IQR Interquartile range
  2. aThe sum does not add up to the total because of missing values